7,863 press releases indexed under healthcare.
Trusted vessel-sealing technology used in more than 45 million procedures worldwide is now cleared for robotic-assisted surgery in the U.S. GALWAY, Ireland, Sept. 16, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and...
(PR-inside.com) LUND, SE / ACCESS Newswire / September 16, 2026 / SynAct Pharma AB (publ) ("SynAct") (STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today announced that the World Health Organization (WHO) has identified resomelagon, the company's once daily oral pro-resolution therapy, as one of six dengue therapeutic candidates with evidence supporting further clinical development. In a review to guide and accelerate clinical development of treatments in dengue, published in Lancet Microbe, WHO outlined a comprehensive review of the global dengue treatment pipeline and named only six candidates with sufficient supporting efficacy data ..
— IASO208 is the first China-originated lentiviral vector-based in vivo CAR-T therapy to receive FDA IND clearance — Supported by early clinical data from an investigator-initiated trial in China, IASO208 is expected to advance directly into a Phase 1b clinical study in the United States...
(PR-inside.com) Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, GB / ACCESS Newswire / September 16, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announced today the results of its previously announced offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to U.S.$250 million aggregate principal amount (the "Maximum Tender Amount") of the Company's 2.032% Senior Notes due 2030 (the "Notes") from each ..
Brainomix joins the UK's leading scale-up programme, alongside some of the country's most promising and growth-focused technology companies Future Fifty selection recognizes Brainomix's continued growth, innovation and international impact in AI-powered medical imaging OXFORD, England and...
First comprehensive global assessment by the International League of Dermatological Societies (ILDS) and L'Oréal Dermatological Beauty spans 158 countries and 97% of the world's population. Summary: The Global Access to Skin Health Observatory Study, published in JAMA Dermatology,...
Wednesday 16 September, 2026 On Sunday, September 20, 2026, we come together to mark World ALL Day, a global campaign aiming to raise awareness of acute lymphoblastic leukemia (ALL) and amplify the voices of patients, as well as the families, caregivers, and communities who support them. The World ALL Day 2026 campaign aims to: Help people feel supported, by sharing real experiences of living with ALL, so patients and caregivers can relate to others who truly understand their journey.Make it easier for those affected by ALL to find and join supportive communities, including patient groups and WhatsApp chats, where they can ask questions and learn from shared experiences.Bring the ALL community together, by encouraging people to share and listen to others, building a sense of belonging and
More than 30 organizations will offer screenings, resources and activities at first-time Treasure Your Health event [PR.com]
Novo to share real-world and clinical data including Wegovy® pill and cardiometabolic pipeline progress with next-generation amylin treatments at EASD
Cancer research has traditionally depended heavily on controlled clinical trials, but the treatment experience that occurs outside those trials is generating an increasingly valuable source [read full press release...]
September 16, 2026 News Release
September 16, 2026 Pressemeddelelse